Individualizing fetal hemoglobin augmenting therapy for β-type hemoglobinopathies patients.

Individualizing fetal hemoglobin augmenting therapy for β-type hemoglobinopathies patients.

Item
http://www.wikidata.org/entity/Q38243173
Current and future alternative therapies for beta-thalassemia majorRecent trends in the gene therapy of β-thalassemia.Population Screening for Hemoglobinopathy Profiling: Is the Development of a Microarray Worthwhile?Whole transcriptome analysis of human erythropoietic cells during ontogenesis suggests a role of VEGFA gene as modulator of fetal hemoglobin and pharmacogenomic biomarker of treatment response to hydroxyurea in β-type hemoglobinopathy patientsPharmacogenomics of sickle cell disease: steps toward personalized medicine.Pharmacogenomics education and research at the Department of Pharmacy, University of Patras, Greece.Correlation of SIN3A genomic variants with β-hemoglobinopathies disease severity and hydroxyurea treatment efficacy.Genomic variants in the ASS1 gene, involved in the nitric oxide biosynthesis and signaling pathway, predict hydroxyurea treatment efficacy in compound sickle cell disease/β-thalassemia patients.
P2860

Individualizing fetal hemoglobin augmenting therapy for β-type hemoglobinopathies patients.

Item
http://www.wikidata.org/entity/Q38243173
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Individualizing fetal hemoglob ...... e hemoglobinopathies patients.
@en
type
label
Individualizing fetal hemoglob ...... e hemoglobinopathies patients.
@en
prefLabel
Individualizing fetal hemoglob ...... e hemoglobinopathies patients.
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P5875
P698
P356
P1433
P1476
Individualizing fetal hemoglob ...... e hemoglobinopathies patients.
@en
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P5875
P698